The papulacandins are a family of antibiotics which were isolated from a strain of Papularia sphaerosperma (Pers.), Hoehnel and which strongly inhibit the growth of Candida albicans'). showed that, in the fungus Geotrichum lactis, papulacandin B inhibits the enzyme 1,3-3-n-glucansynthase3). The corresponding enzyme from S. cerevisiae was only slightly inhibited by high concentrations of the drug (E. CABIB, personal communication). Thus the precise mechanism of action of the papulacandins remains to be elucidated.
The natural papulacandins, their degradation products and semisynthetic derivatives differ quite strongly in their ability to inhibit the growth of Candida albicans. Such differences could be due to varying degrees of activity at the site of action. Alternatively, other factors, such as degradation of compounds during microbial testing, or differences in the rate of penetration into the fungal cell could play an important role.
In this paper, the structural requirements of the papulacandin molecule for activity at the target site have been investigated.
Materials and Methods
The papulacandin derivatives described here have either been isolated from cultures of Papularia sphaerosperma or synthesized in our laboratories from papulacandin B. To measure glucan biosynthesis, Candida albicans K 1133, a standard test strain of our laboratories was used. The growth of the cells, the preparation and incubation of spheroplasts, the measurement of the glucan synthesis and the growth inhibition of Candida albicans K 1133 by the various derivatives were carried out as described in detail by BAGULEY et al.4>.
Results
As shown in Fig From Table 1 it is evident that papulacandin B2 is the most active compound both in growth inhibition (MIC) and inhibition of glucan biosynthesis. Slight structural changes of the short fatty acid (papulacandin A (1) or papulacandin C (3)) have only a minor effect on the biological activity. Hydrogenation of both fatty acid residues (compound 5) or removal of the short fatty acid (compound 8, see Fig. 3 ) does not greatly affect the action on glucan biosynthesis, whereas growth inhibition is no longer found (MIC > 128 lrg/ml). Papulacandin D (4, Fig. 2 ), a derivative without short fatty acid and galactose residue, is still a quite active compound at both the target site and in respect to its MIC . On the other hand hydrogenation of papulacandin D (compound 6) clearly reduces the biological activity .
Removal of both fatty acid residues (compound 9) or the additional removal of the galactose moiety (compound 10, see Fig. 3 ) leads to a total loss of activity. The same is true for papulacandin B nona- 
Conclusions
The biological analysis of a series of papulacandin derivatives shows that clear differences exist between the structural requirements for effective action at the target site of the drugs, namely the inhibition of the glucan biosynthesis, and the reaching of the target site, a parameter important for the inhibition of fungal growth (MIC).
The following conclusions can be made from the results:
The presence of the long fatty acid residue is an absolute requirement for activity at the target site. Removal of this residue from the degradation product 8, which is still active at the target site, gives the inactive degradation product 9. The results obtained with papulacandin D (4) prove that neither the presence of the short fatty acid nor the galactose moiety are essential for biological activity.
Apparently the degradation product 8 does not reach the target site.
Hydrogenation
of the fatty acids (compounds 5 and 6) leads to a loss of activity.
In this case, penetration to the target site seems to be more strongly influenced.
The derivatives synthesized so far with substitutions in the diglucoside nucleus show activities in most cases similar to those of papulacandin B. These data lead one to conclude that less complex derivatives such as papulacandin D may be good starting material for further chemical modifications to obtain more active compounds.
